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Abstract
Through the years, epinephrine has been the drug of choice for patients with cardiogenic shock. However, epinephrine was
clinically inferior to norepinephrine in comparison studies because of the negative patient outcomes, which were statistically
significant. These effects include type B lactic acidosis, tachycardia, increased myocardial oxygen demand, and arrhythmias.
Keywords: cardiogenic shock, epinephrine, norepinephrine

Background
In theory, epinephrine is good for clinical use. It is a
catecholamine with a high affinity for alpha-1, beta-1, and
beta-2 receptors and is commonly used in ~20-40% of patients
with cardiogenic shock.1 However, it is important to note that
because of the high affinity for beta-1 and beta-2 receptors, the
use of epinephrine can lead to increased chronotropy and
inotropy. These increases, along with vasoconstriction, cause
an increase in mean arterial pressure (MAP) and coronary
blood flow relative to an increased duration in diastole.
Ironically, even though it is sometimes known as “high dose”
norepinephrine, epinephrine in high doses can cause even
stronger effects due to its alpha-receptor affinity.

The Downsides
From a hemodynamic perspective, one of the downsides
of epinephrine use is increased afterload, which can cause
decreased cardiac output. High-dose usage of epinephrine
causes increased pulmonary vascular resistance, increasing
right ventricular afterload. Epinephrine also results in an
increased heart rate and stroke work, which increases

myocardial oxygen demand. Unsurprisingly, this stimulation
of the heart can cause arrhythmias. Other downsides include
cardiac toxicity with arterial wall damage and necrosis,
stimulation of myocyte apoptosis, hyperglycemia, insulin
resistance, and type B lactic acidosis.

Comparison Studies
In a study of the hemodynamic effects of epinephrine,
norepinephrine, and phenylephrine in rats, epinephrine use
showed a significant increase in heart rate and an increase in
cardiac output and myocardial oxygen demand.2 A mechanism
common with these characteristics is tachycardia.
In a randomized trial of under 300 patients, with
approximately half with cardiogenic shock, epinephrine and
norepinephrine had similar effects on MAP.3 However, as
seen in the rat model, there was still an increase in heart rate,
lactate, and insulin dose needed.
A smaller study of 30 randomized patients with
cardiogenic shock compared epinephrine to norepinephrinedobutamine. MAP and cardiac index were similar for both
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drugs, but higher lactate and heart rates were seen with
epinephrine use. In addition, epinephrine appeared to cause
less diuresis.4

Epinephrine versus Norepinephrine
Following this small trial, a larger randomized study
compared epinephrine to norepinephrine and included 57
patients with acute myocardial infarction complicated by
cardiogenic shock. As seen with the other studies, MAP was
similar between the two groups.5 In addition, the epinephrine
groups had higher lactate, a higher incidence of tachycardia,
and increased myocardial oxygen demand. The trial was
stopped early because there was a statistically significant
signal of harm seen with the use of epinephrine; the incidence
of refractory shock was 37% vs. 7% in the epinephrine vs. the
norepinephrine groups, respectively.

Conclusion
In conclusion, epinephrine use in cardiogenic shock is
associated with excess lactic acid (mainly type B lactic
acidosis), tachycardia, increased myocardial oxygen demand,
and increased arrhythmias. In small trials, norepinephrine
seems clinically superior to epinephrine for patients with
cardiogenic shock, and larger observational studies have
demonstrated higher mortality rates with epinephrine use.
Despite this data, epinephrine is still widely used.
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